At the news
? BULLISHIMPACT 7/10 PRESS-RELEASE filed Jun 3, 2026 at 06:00 ET
Mineralys Therapeutics repurchased its royalty obligation to Tanabe for $200M upfront (up to $100M in milestones), secured a $500M debt facility from Pharmakon (first tranche $100M), and priced a $150M common stock offering. The transactions eliminate future royalty payments, strengthen the balance sheet, and provide capital to support lorundrostat's commercialization ahead of an NDA review.
- Repurchased all future royalty payments to Tanabe for $200M upfront plus up to $100M in commercial milestones
- Entered $500M senior secured term loan facility with Pharmakon Advisors; first tranche of $100M funded at closing
- Priced $150M common stock offering
- Tanabe to assign intellectual property rights for lorundrostat to Mineralys
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access